Parvovirus B19 Immunity among Iranian patients with Human Immunodeficiency Virus (HIV) infection
Human Parvovirus B19 (PVB19) is among the etiology of aplastic crisis in HIV infected patients. Although studies have indicated the importance of such an infection among immunocopromised patients, seroprevalence of this infection differs worldwide. The current study aims to determine the seropreval...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2014-08-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | https://mjhid.org/index.php/mjhid/article/view/1724 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Human Parvovirus B19 (PVB19) is among the etiology of aplastic crisis in HIV infected patients. Although studies have indicated the importance of such an infection among immunocopromised patients, seroprevalence of this infection differs worldwide.
The current study aims to determine the seroprevalence of IgM and IgG antibodies to PVB19 among HIV positive patients and its association with clinical and epidemiological factors in a large referral hospital in Iran.
In a cross sectional study, 90 HIV positive patients were compared with 90 healthy subjects in terms of anti PVB19 IgG and IgM along with other primary clinical and laboratory features.
The mean ± SD CD4+ and CD8+ cell counts in case group was 281.18±188.43 and 775.94±374.77, respectively with no statistically significant difference (p>0.05). The overall prevalence of detected anti PVB19 IgG was 81.1% in case group and 28.9% in the control group which differed significantly between the two groups (p>0.05). Moreover, none of the subjects showed positive results for anti PVB19 IgM.
Seroprevalence of anti PVB19 may differ between HIV positives and health population. However, the presence of anti PVB19 IgG does not necessarily protect the body from further complications like anemia. Present difference between antiretroviral regimens for seroprevalnce of anti PVB19 IgG should be further studied. |
|---|---|
| ISSN: | 2035-3006 |